Show simple item record

Authordc.contributor.authorSepúlveda, Pablo 
Authordc.contributor.authorHameau, René 
Authordc.contributor.authorBackhouse, Christian 
Authordc.contributor.authorCharme, Gustavo 
Authordc.contributor.authorPacheco, Francisco 
Authordc.contributor.authorRamírez, Pablo A. 
Authordc.contributor.authorFuensalida, Alberto J. 
Authordc.contributor.authorQuitral, Jorge 
Authordc.contributor.authorMartínez, Gonzalo 
Authordc.contributor.authorMartínez, José A. 
Cita de ítemdc.identifier.citationCatheter Cardiovasc Interv. 2020;1–10es_ES
Abstractdc.description.abstractObjectives To describe the characteristics of patients who undergo balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and report the mid-term outcomes. Background BPA has been recently introduced in Latin America. Mid-term results have not been published. Methods Prospective Chilean Registry of inoperable CTEPH patients who underwent BPA. Clinical variables were analyzed at baseline, after each procedure and at follow-up. Hemodynamic variables were recorded before and after the last BPA. Results Between August 2016 and September 22, 2019 patients (17 women), 59 +/- 12.7 years, underwent 81 BPA and were followed for as long as 33.1 months (mean 17.3 +/- 7.5). Mean pulmonary artery pressure decreased by 17.4% (51.1 +/- 12 vs. 42.2 +/- 13 mmHg,p= .001), pulmonary vascular resistance by 23.9% (766.7 +/- 351 vs. 583 +/- 346 dynes/s/cm(-5),p= .001), cardiac index increased by 8% (2.3 +/- 0.54 vs. 2.5 +/- 0.54 L/min/m(2),p= .012), N-terminal pro-B-type natriuretic peptide decreased by 73.8% (1,685 +/- 1,045 vs. 441.8 +/- 276 pg/dl,p= .006), and 6-min walk distance improved by 135 m (316.7 +/- 94 vs. 451.1 +/- 113 m,p= .001). One patient (4.5%) developed lung reperfusion injury and four patients (18.2%) had minor bleeding (hemoptysis), after the procedure. There was no mortality associated with BPA. Conclusions Our results confirm that BPA for inoperable CTEPH is a relatively safe procedure that improves clinical and hemodynamic parameters in the mid-term. This therapy should be considered as an alternative, mainly in places where access to PAH therapy or surgery is restricted.es_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.uri*
Sourcedc.sourceCatheterization and Cardiovascular Interventionses_ES
Keywordsdc.subjectChronic thromboembolic pulmonary hypertensiones_ES
Keywordsdc.subjectPulmonary hypertensiones_ES
Títulodc.titleMid-term follow-up of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: An experience in Latin Americaes_ES
Document typedc.typeArtículo de revista
dcterms.accessRightsdcterms.accessRightsAcceso Abierto
Indexationuchile.indexArtículo de publicación ISIes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile